Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
2020-06-01 07:30
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
2020-06-01 07:30
Establishment of the Blue Apple New Frontier Healthcare Fund
2020-06-01 07:00
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
2020-05-31 20:00
Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients
2020-05-30 19:00
Fosun Foundation and Longfor Group donated 40 ventilators to the U.S. hospitals in fight against COVID-19
2020-05-30 02:00
The 2nd Singapore-China Joint Meeting on COVID-19
2020-05-30 00:56
New England Journal of Medicine Publishes Primary Analysis of VISION Data for Tepotinib in Advanced NSCLC with METex14 Skipping Alterations
2020-05-29 20:33
I-Mab Announces Upcoming Participation at June Conferences
2020-05-29 20:00
Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)
2020-05-29 20:00
Mundane Glory: Telling the Story of Chinese Overseas Medical Aid
2020-05-29 17:41
Zlatko Rihter Appointed New CEO of Moelnlycke
2020-05-29 15:13
Jakarta-Based Home of Wellbeing Rumah Remedi Held #stayathome Meditations During the Pandemic
2020-05-29 12:41
Thailand's Economic Front in Fighting COVID-19
2020-05-29 12:20
Overcoming Challenges to Offline Education, Mysavvytutor Advances with New On-Demand App
2020-05-29 10:00
Ping An Voyager Fund Leads Investment in PlusDental to Enhance Modern Dentistry in Europe
2020-05-29 09:48
Zai Lab Announces Positive Topline Results from the NORA Phase 3 Study of ZEJULA® as Maintenance Therapy for Chinese Patients with Platinum-sensitive, Recurrent Ovarian Cancer
2020-05-29 07:05
Endofotonics Raises S$12 million in Series B Funding for the Commercialization of its AI Powered Medical Device to Support Clinicians in the Real Time Detection of Early Stomach Cancer
2020-05-29 07:00
1
769
770
771
772
773
1597